目的:纳米颗粒可用于提高天然产物的治疗活性。2型糖尿病是一种严重的健康状况,已经像“现代大流行”一样在世界范围内蔓延。在本研究中,我们开发了银纳米粒子,AgNPs,用Balanites的水提物研究其在STZ诱导的糖尿病大鼠中的抗氧化和抗炎活性。
方法:在BAAE-AgNPs的合成中使用了Balanitesagyptiaca种子(BAAE)的水提物,用FTIR和TEM表征。向STZ诱导的糖尿病大鼠施用不同剂量的BAAE-AgNP(1/50LD50;29.4mg/kgb.w.和1/20LD50:73.5mg/kgb.w.)以评估其潜在的抗糖尿病活性。
结果:FTIR光谱数据表明BAAE-AgNP中存在类黄酮和多酚。BAAE-AgNPs的大小,通过TEM检查确定,为49.33±7.59nm,zeta电位为+25.37。BAAE-AgNPs的特征是LD50值为1470mg/kgb.w。在糖尿病大鼠中,每天口服两种剂量的BAAE-AgNPs(29.4和73.5mg/kgb.w.)12周导致体重的显着改善,胰岛素稳态,HbA1c,HDL-C,MDA,和胰腺SOD,CAT,GSH。他们降低了血浆葡萄糖,胆固醇,和甘油三酯。这种治疗还导致糖尿病大鼠胰腺IL-6,P53和TNF-α的显着降低。此外,BAAE-AgNPs下调糖尿病大鼠胰腺TGF-β1和Akt基因的表达,导致肝脏GLUT-2的调节显著降低,以及肝脏GK和胰腺B-cl2基因表达的调节增加。获得的组织病理学结果表明,BAAE-AgNPs通过增强抗氧化酶改善胰腺组织代谢,抑制炎症细胞因子,清除自由基.
结论:研究结果暗示与格列本脲治疗组相似,在BAAE-AgNPs治疗组中,受损的抗氧化剂状态在STZ诱导的糖尿病中正常化。通过清除自由基,BAAE-AgNPs防止脂质过氧化,同时降低糖尿病并发症的风险。与29.4mg的日剂量相比,73.5mg时影响更为显著.
OBJECTIVE: Nanoparticles can be employed to improve the therapeutic activity of natural products. Type 2 diabetes mellitus is a serious health condition that has spread like a \"modern pandemic\" worldwide. In the present study, we developed silver nanoparticles, Ag-NPs, with an aqueous extract from Balanites aegyptiaca to investigate their antioxidant and anti-inflammatory activity in STZ-induced diabetic rats.
METHODS: Aqueous extracts of Balanites aegyptiaca seeds (BAAE) were used in the synthesis of BAAE-AgNPs, which were characterized using FTIR and TEM. Different doses of BAAE-AgNP (1/50 LD50; 29.4 mg/kg b.w. and 1/20 LD50: 73.5 mg/kg b.w.) were administered to STZ-induced diabetic rats to evaluate their potential antidiabetic activity.
RESULTS: FTIR spectral data indicated the presence of flavonoids and polyphenols in BAAEAgNPs. The size of the BAAE-AgNPs, determined by TEM examination, was 49.33 ± 7.59 nm, with a zeta potential of +25.37. BAAE-AgNPs were characterized by an LD50 value of 1470 mg/kg b.w. In diabetic rats, the daily oral administration of both doses of BAAE-AgNPs (29.4 and 73.5 mg/kg b.w.) for 12 weeks resulted in a significant improvement in body weight, insulin homeostasis, HbA1c, HDL-C, MDA, and pancreatic SOD, CAT, and GSH. They reduced plasma glucose, cholesterol, and triglycerides. This treatment also resulted in a significant decrease in pancreatic IL-6, p53, and TNF-α in diabetic rats. Furthermore, BAAE-AgNPs down-regulated pancreatic TGF-β1 and Akt gene expression in diabetic rats and resulted in a significant decrease in the regulation of hepatic GLUT-2, as well as an increase in the regulation of hepatic GK and pancreatic B-cl2 gene expression. The histopathological results obtained indicated that BAAEAgNPs improved pancreatic tissue metabolism by enhancing antioxidant enzymes, suppressing inflammatory cytokines, and scavenging free radicals.
CONCLUSIONS: The findings implied that similar to the glibenclamide-treated groups, in the BAAEAgNPs treated group, the compromised antioxidant status normalized in STZ-induced diabetes. By scavenging free radicals, BAAE-Ag-NPs protected against lipid peroxidation while reducing the risk of complications from diabetes. Compared to the daily dose of 29.4 mg, the impact was more prominent at 73.5 mg.